Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia.

Nobuko HijiyaC Michel ZwaanCarmelo RizzariRobin FoàFloor AbbinkDonna LancasterJudith Landman-ParkerFrédéric MillotJohn MoppettBrigitte NelkenMaria Caterina PuttiXianbin TianKaren SinclairHelene SantanastasioAby BuchbinderPamela Kearns

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Nilotinib 230 mg/m2 twice daily in pediatric patients provided a pharmacokinetics and safety profile comparable with the adult reference dose; clinical activity was demonstrated in both CML and Ph+ ALL. This dose is recommended for further evaluation in pediatric patients. The safety profile was consistent with that in adults.

Keyphrases

chronic myeloid leukemia
acute lymphoblastic leukemia
physical activity
gene expression
acute myeloid leukemia
young adults